Feature Channels:

Personalized Medicine

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Center for Individualized Medicine, Dna Sequencing, Medical Research, Minnesota News Releases, Molecular Testing, news releases, Pharmacogenomics, Precision Medicine

Mayo Clinic Patient: ‘Individualized Medicine Saved My Life’

What Karen Daggett didn’t know almost killed her. The medicine she relied on to control an irregular heartbeat wasn’t working and hadn’t for years and she didn’t understand why pain medication never seemed to make her feel better. She also had a history of not tolerating some over-the-counter medications. Silently, these drugs were building up in her system, causing harmful side effects until DNA testing at Mayo Clinic Center for Individualized Medicine showed some medications were incompatible with her genetic makeup.

Medicine

Channels:

Alzheimer's Disease, Georgetown University Medical Center, Howard Fillit, Nilotinib, repurposing cancer drugs, R. Scott Turner, Chronic Myeloid Leukemia, Cognitive Impairment, Neuroinflammation, misfiled proteins, atophagy, plaques and tangles, tau, beta-amyloid, Charbel Moussa, Georgetown Memory Disorders Program, anti-neurodegenerative drug, Georgetown U

New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment

ADDFlogo.jpg

The Alzheimer’s Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna® for use as a cancer therapy) in patients with Alzheimer’s disease.

Medicine

Channels:

Hepatitis, Hepatitis B, Hepatitis B research, Hepatitis B Virus, hepatitis B virus (HBV), pharmacological research, Pharmacology, Pharmacologic, pharmacologic compound, pharmacology and therapeutics, Drug Research, Drug Research and Development

NIH Grants MU $3 Million to Develop New Hepatitis B Treatments

SarafianosStefan.jpg

Hepatitis B (HBV) is a viral infection that increases the likelihood of developing liver cancer or liver failure. According to the World Health Organization, an estimated 2 billion people currently are infected with HBV, which is more than 10 times the number of people who have human immunodeficiency virus (HIV). Currently, treatment for hepatitis B infections is limited to one class of drugs that targets the virus. Stefan Sarafianos, an investigator with the University of Missouri Bond Life Sciences Center (BLSC) recently was awarded $3 million from the National Institutes of Health to study the disease. Building on existing research, he and his team will work on the development of new drugs to treat HBV.

Medicine

Channels:

Inside the Lab: Using Botox to Advance Science

Many know Botox as a trendy way to get rid of wrinkles, but the popular drug — made from botulinum neurotoxin (BoNT) — can do more than just fill lines.

Medicine

Channels:

drug deliver, Tumor, Cancer, magnetic bacteria

Swarms of Magnetic Bacteria Could Be Used to Deliver Drugs to Tumors

Magneticbacteriaillustration.jpg

Researchers have recently shown that magnetic bacteria are a promising vehicle for more efficiently delivering tumor-fighting drugs.

Medicine

Channels:

Drug Restores Hair Growth in Patients with Alopecia Areata

Seventy-five percent of patients with an autoimmune disease that causes hair loss had significant hair regrowth after treatment with ruxolitinib, according to a study from Columbia University Medical Center.

Medicine

Channels:

Breast Cancer, Cancer Biomarkers, Genomics, cancer disparities, cancer drug resistance, cancer drug development

UCSF Researchers Awarded Breast Cancer Research Funding From Susan G. Komen

pippettingimage.jpg

Three UCSF researchers have been awarded $680,000 in grants from Susan G. Komen to support projects in breast cancer research. The grants to UCSF were among a total of $32.7 million given to researchers in 23 states and seven countries for projects including research into metastatic disease, novel treatments for aggressive types of breast cancer, new technologies, and health equity.

Medicine

Channels:

antibiotic resisistance, Antibiotic Resistant Bacteria, Keratitis, Superbug, Superbugs

Mass. Eye and Ear Team Discovers, Successfully Treats New Variant of Antibiotic-Resistant Bacterium

Researchers at Massachusetts Eye and Ear have discovered a new mutation in a highly antibiotic-resistant strain of E. coli that resists clearance by the body’s own immune system by inhibiting white blood cells that ordinarily kill and remove bacteria. In a paper published online today in JAMA Ophthalmology, the researchers describe the case that led them to discover the mutation, and offer suggestions for how to recognize and address this particular microbe if encountered in the future.

Medicine

Channels:

Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, Tisch Cancer Institute, Ras inhibitor, KSR, Nature, Cancer Therapeutics, Cancer Therapies, Oncogene

Mount Sinai Researchers Identify New Therapeutic Target for Cancer

New research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapies. The protein, known as kinase suppressor of Ras, or KSR, is a pseudoenzyme that plays a critical role in the transmission of signals in the cell determining whether cells grow, divide, or die.

Medicine

Channels:

Mouse Model Points to Potential Drug Target for Increasing Social Interaction in Autism

BrodkinamygdalacellsSept16.jpg

A study of a new mouse model identifies a drug target that has the potential to increase social interaction in individuals with some forms of autism spectrum disorder.







Chat now!